BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38642218)

  • 1. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
    Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
    Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quebec Health-related Quality of Life Population Norms in Adults Using the SF-6Dv2: Decomposition by Sociodemographic Data and Health Problems.
    Poder TG; Carrier N
    Med Care; 2022 Jul; 60(7):545-554. PubMed ID: 35471260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Nahvijou A; Safari H; Ameri H
    Breast Cancer; 2021 Jul; 28(4):937-943. PubMed ID: 33666840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in health utilities between cancer patients and the general population: The case of Quebec using the SF-6Dv2.
    Touré M; Poder TG
    Soc Sci Med; 2024 Jun; 351():117001. PubMed ID: 38805836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec.
    Poder TG; Wang L; Carrier N
    BMJ Open; 2020 Sep; 10(9):e035722. PubMed ID: 32933957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.
    Poder TG; Fauteux V; He J; Brazier JE
    Value Health; 2019 Jul; 22(7):837-842. PubMed ID: 31277832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SF-6Dv2 preference value set for health utility in food allergy.
    Dufresne É; Poder TG; Samaan K; Lacombe-Barrios J; Paradis L; Des Roches A; Bégin P
    Allergy; 2021 Jan; 76(1):326-338. PubMed ID: 32533705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Norms for SF-6Dv2 and EQ-5D-5L in China.
    Xie S; Wu J; Xie F
    Appl Health Econ Health Policy; 2022 Jul; 20(4):573-585. PubMed ID: 35132573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
    Nahvijou A; Safari H; Yousefi M; Rajabi M; Arab-Zozani M; Ameri H
    Breast Cancer; 2021 Jan; 28(1):130-136. PubMed ID: 32712768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
    Xie S; Wang D; Wu J; Liu C; Jiang W
    Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems.
    Poder TG; Carrier N; Kouakou CRC
    Value Health; 2020 Feb; 23(2):251-259. PubMed ID: 32113631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.
    Daroudi R; Zeraati H; Poder TG; Norman R; Olyaeemanesh A; Sari AA; Ameri H
    Qual Life Res; 2024 Jul; 33(7):1853-1863. PubMed ID: 38630166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.
    Brazier JE; Mulhern BJ; Bjorner JB; Gandek B; Rowen D; Alonso J; Vilagut G; Ware JE;
    Med Care; 2020 Jun; 58(6):557-565. PubMed ID: 32412942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
    Mulhern BJ; Bansback N; Norman R; Brazier J;
    Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second Version of the Short Form 6-Dimension Value Set Elicited From Patients With Breast and Colorectal Cancer: A Hybrid Approach.
    Touré M; Pavic M; Poder TG
    Med Care; 2023 Aug; 61(8):536-545. PubMed ID: 37308990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the consistency of the SF-6Dv2 in a breast cancer population.
    Ameri H; Safari H; Poder T
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1017-1024. PubMed ID: 33107340
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting SF-6Dv2 utility scores for chronic low back pain using the Oswestry Disability Index and Roland-Morris Disability Questionnaire.
    Poder TG; Carrier N
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):105-110. PubMed ID: 32275183
    [No Abstract]   [Full Text] [Related]  

  • 18. SF-6D population norms for the Hong Kong Chinese general population.
    Wong CKH; Mulhern B; Cheng GHL; Lam CLK
    Qual Life Res; 2018 Sep; 27(9):2349-2359. PubMed ID: 29797176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students.
    Zhou HJ; Zhang A; Wei J; Wu J; Luo N; Wang P
    BMC Public Health; 2023 Nov; 23(1):2314. PubMed ID: 37993793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.
    Xie S; Li M; Wang D; Hong T; Guo W; Wu J
    Health Qual Life Outcomes; 2023 Oct; 21(1):118. PubMed ID: 37904216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.